Quadrant Capital Group’s Terns Pharmaceuticals TERN Stock Holding History

Quadrant Capital Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$52.6K	Sell	998 -167	-14%	-$6.86K	﹤0.01%	1682
2025 Q4	$47.1K	Hold	1,165	–	–	﹤0.01%	1711
2025 Q3	$8.75K	Buy	+1,165	New	+$7.44K	﹤0.01%	2197
2024 Q2	–	Sell	-1,814	Closed	-$11.9K	–	2767
2024 Q1	$11.9K	Buy	1,814 +1,475	+435%	+$9.63K	﹤0.01%	2041
2023 Q4	$2.2K	Buy	+339	New	+$1.79K	﹤0.01%	2460

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Quadrant Capital Group's TERN Position: Q1 2026 in Review

Quadrant Capital Group reduced its Terns Pharmaceuticals (TERN) stake by 14% in Q1 2026, selling an estimated $6.86K and leaving 998 shares worth $52.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

Quadrant Capital Group first reported a position in TERN in Q4 2023 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Quadrant Capital Group held 998 shares of Terns Pharmaceuticals worth $52.6K as of Q1 2026.
Quadrant Capital Group sold 167 Terns Pharmaceuticals shares in Q1 2026, an estimated $6.86K.
Terns Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1682 holding.
Quadrant Capital Group first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.